Company Page - MANNKIND CORP

28903 North Avenue Paine	Research Report	Earnings Snapshot - Last 11/03/18
Valencia, CA 91355	Fact Sheet
Phone: (661) 775-5300	Financial Statements
	Peer Comparison
	Annual Reports

Alfred E. Mann, Chmn./CEO, Hakan S. Edstrom, Pres./COO, Richard L. Anderson, CFO
Biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. Our lead product, the Technosphere Insulin System, which in late Phase II clinical trials for the treatment of diabetes, a dry powder Technosphere formulation of insulin and MedTone inhaler through which the powder is inhaled into the deep lung. IPO at $14 July 27, 2004. Raised $87.5 million, selling 6.3 million shares, 20% of the outstanding. Lead Manager: UBS Securities.

Historical Charts Technical Analysis

No Historical Data available for MNKD

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)

Common MNKD $1.31 $1.31 0 .0 $1.22 $1.32 1,201,086 $1.22 $1.32 213,128,580

Warrants MNKDW $2.41 $ 0 $2.41 $2.41 100 $.41 $4 0

Warrants MNKIW $3.5925 $ 0 $3.5925 $3.5925 100,000 $.15 $4.265 0

Capitalization
Earnings Summary ()
*** No Earnings Available***
-10126

Common Stock $279,198,440

QUICK NAVIGATION			SITE SEARCH Enter Keyword:

Home Subscribe Browser Help Subscriber Services B-to-B Banks Brokerage Telco Site Map Legal Contact/Email
Copyright © 1996 - 2025 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex